{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "firstTradeDateMilliseconds": 1623996000000, "priceHint": 4, "epsTrailingTwelveMonths": -0.24, "sharesOutstanding": 40068300, "bookValue": 3.372, "fiftyDayAverage": 0.61546, "fiftyDayAverageChange": 0.17454004, "fiftyDayAverageChangePercent": 0.28359285, "twoHundredDayAverage": 0.740825, "twoHundredDayAverageChange": 0.049175024, "twoHundredDayAverageChangePercent": 0.066378735, "marketCap": 31653958, "priceToBook": 0.23428233, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": -13.186812, "regularMarketPrice": 0.79, "marketState": "REGULAR", "exchange": "FRA", "shortName": "LYTIX BIOPHARMA  NK -,10", "longName": "Lytix Biopharma AS", "messageBoardId": "finmb_30221892", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": -0.120000005, "regularMarketTime": 1683871386, "regularMarketDayHigh": 0.79, "regularMarketDayRange": "0.79 - 0.79", "regularMarketDayLow": 0.79, "regularMarketVolume": 2877, "regularMarketPreviousClose": 0.91, "bid": 0.73, "ask": 0.865, "fullExchangeName": "Frankfurt", "financialCurrency": "NOK", "regularMarketOpen": 0.79, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.27000004, "fiftyTwoWeekLowChangePercent": 0.51923084, "fiftyTwoWeekRange": "0.52 - 1.205", "fiftyTwoWeekHighChange": -0.41500002, "fiftyTwoWeekHighChangePercent": -0.34439835, "fiftyTwoWeekLow": 0.52, "fiftyTwoWeekHigh": 1.205, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "6BG.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sandakerveien 138", "city": "Oslo", "zip": "0484", "country": "Norway", "website": "https://www.lytixbiopharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. The company was incorporated in 2003 and is based in Oslo, Norway.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Oystein  Rekdal Ph.D.", "title": "Co-Founder & CEO", "fiscalYear": 2022, "totalPay": {"raw": 388657, "fmt": "388.66k", "longFmt": "388,657"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Gjest  Breistein M.Sc.", "title": "Chief Financial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Gry  Stensrud Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Baldur  Sveinbj\u00f8rnsson Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Graeme  Currie Ph.D.", "title": "Chief Devel. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 59, "title": "Chief Bus. Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ole Peter Nordby", "title": "Head of IR & Communication Mang.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Jacqueline  Earabino", "title": "Head of Clinical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}